{"entity":{"id":"nct07015853","kind":"trial","name":"ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation","aka":[],"tldr":"A phase 2 trial of pembrolizumab in triple-negative breast cancer, run by Stephen Shiao, not yet recruiting.","summary":"ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation is a phase 2, interventional study registered as NCT07015853 by Stephen Shiao, with a registry enrolment figure of 34 participants, started 2026-06 and due to reach its primary completion in 2033-07. Interventions recorded: Pembrolizumab; Radiotherapy; Axatilimab. Conditions listed: TNBC - Triple-Negative Breast Cancer; Breast Cancer. Triple-negative eligibility wording from the registry: \"* Patients with metastatic or locally recurrent TNBC who received prior immunotherapy in any setting (curative or advanced/metastatic)\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07015853","url":"https://clinicaltrials.gov/study/NCT07015853"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07015853","phase":"2","setting":"IIT2024-02-SHIAO-ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation","sponsor":"Stephen Shiao","enrolled":34,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07015853/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}